Congress and the Florida Legislature must eliminate cost disparities between opioid and non-opioid options.

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

A research team has developed a non-opioid medication that shows promise in treating acute and chronic pain. The drug, known ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Chronic pain, which lasts for three months or longer, is difficult to treat. Many people rely on opioid pain medications, but ...

During my time serving in the state legislature, I heard from numerous constituents impacted by the opioid crisis ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

You raise both non-dilutive funding through NIH which is the very best, obviously, and then as well as dilutive and to try to move the program forward. PE:How risky is the traditional pain medication ...

s new non-opioid painkiller is being placed for now on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists. The medication ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...